(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are KONGSBERG AUTOMOT, POLIGHT, and HAVILA SHIPPING.

Financial Asset	Price	Change	Updated (EST)
KONGSBERG AUTOMOT (KOA.OL)	1.86	14.15%	2024-09-12 12:41:00
POLIGHT (PLT.OL)	4.61	13.7%	2024-09-12 12:42:27
HAVILA SHIPPING (HAVI.OL)	3.57	11.41%	2024-09-12 12:40:23
VIVORYON (VVY.AS)	2.08	9.53%	2024-09-12 12:04:43
MOTORK (MTRK.AS)	5.80	8.21%	2024-09-12 12:03:03
VOW (VOW.OL)	2.76	7.62%	2024-09-12 12:44:22
IBA (IBAB.BR)	12.62	6.96%	2024-09-12 12:20:13
SALMONES CAMANCHAC (SACAM.OL)	22.00	6.8%	2024-09-12 12:42:49
ENDÚR (ENDUR.OL)	62.10	6.7%	2024-09-12 12:25:57
BENEVOLENTAI (BAI.AS)	0.84	6.22%	2024-09-12 12:00:53

The three biggest losers today are ULTIMOVACS, NYRSTAR, and AELIS FARMA.

Financial Asset	Price	Change	Updated (EST)
ULTIMOVACS (ULTI.OL)	1.90	-21.97%	2024-09-12 12:44:11
NYRSTAR (NYR.BR)	0.04	-17.75%	2024-09-12 12:20:52
AELIS FARMA (AELIS.PA)	4.36	-16.95%	2024-09-12 12:45:14
OXURION (OXUR.BR)	0.70	-10.71%	2024-09-12 12:21:02
HYLORIS (HYL.BR)	5.18	-9.57%	2024-09-12 12:20:11
LAVIDE HOLDING (LVIDE.AS)	0.22	-8.26%	2024-09-12 12:02:51
NRC GROUP (NRC.OL)	3.23	-7.32%	2024-09-12 12:41:46
HYDRATEC (HYDRA.AS)	139.00	-6.71%	2024-09-12 12:02:33
ASSYSTEM (ASY.PA)	46.05	-6.41%	2024-09-12 12:46:02
REC SILICON (RECSI.OL)	6.32	-5.53%	2024-09-12 12:42:40

Winners today

1. KONGSBERG AUTOMOT (KOA.OL)

14.15% Price Change

Kongsberg Automotive ASA develops, manufactures, and sells products to the automotive industry worldwide. The company operates through Powertrain & Chassis and Specialty Products segments. The Powertrain & Chassis segment designs, manufactures, and tests custom-engineered cable controls and shift systems, clutch actuation systems, vehicle dynamics, shift cables, and shift towers for transmissions. The Specialty Products segment offers fluid handling systems; couplings systems for compressed-air circuits in heavy-duty vehicles; and operator control systems for power sports construction, agriculture, outdoor power equipment, and power electronics products. It serves OEMs and Tier 1 suppliers in the automotive, commercial vehicle, passenger car, and off-highway markets. The company was formerly known as Kongsberg Automotive Holding ASA and changed its name to Kongsberg Automotive ASA in August 2014. Kongsberg Automotive ASA was founded in 1957 and is based in Kongsberg, Norway.

Oslo Børs Benchmark Index_GI ended the session with KONGSBERG AUTOMOT rising 14.15% to €1.86 on Thursday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, KONGSBERG AUTOMOT has a trailing twelve months EPS of kr-0.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.4%.

Sales Growth

KONGSBERG AUTOMOT’s sales growth is 0.3% for the current quarter and negative 1% for the next.

More news about KONGSBERG AUTOMOT.

2. POLIGHT (PLT.OL)

13.7% Price Change

poLight ASA develops optical lens for consumer devices and industrial applications in Europe, Asia, and the United States. The company's lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes TLens, a tuneable optical lens for autofocus camera applications; Packaged TLens that facilitates integration of a TLens on a fixed-focus camera module; driver ASIC is designed to drive capacitive loads such as the TLens autofocus actuators; and evaluation kits that allows to test and evaluate the optical and electrical performance of the TLens in new products and/or applications. It serves smartphones and wearables, industrial, augmented reality, healthcare, and webcams markets. poLight ASA was founded in 2005 and is headquartered in Skoppum, Norway.

Oslo Børs Benchmark Index_GI ended the session with POLIGHT rising 13.7% to €4.61 on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-1.12.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.09%.

Moving Average

POLIGHT’s worth is way above its 50-day moving average of kr3.79 and way under its 200-day moving average of kr8.28.

Revenue Growth

Year-on-year quarterly revenue growth declined by 26.8%, now sitting on 14.74M for the twelve trailing months.

Volume

Today’s last reported volume for POLIGHT is 1052190 which is 3.62% below its average volume of 1091780.

More news about POLIGHT.

3. HAVILA SHIPPING (HAVI.OL)

11.41% Price Change

Havila Shipping ASA, together with its subsidiaries, engages in the shipping business. It manages and operates offshore service vessels primarily in Norway, the United Kingdom, Denmark, Belgium, the Netherlands, Iceland, Tunisia, the Marshall Islands, and the United States. The company operates a fleet of vessels, including anchor handling vessels, platform supply vessels, rescue recovery vessel, and subsea vessels. Its subsea vessels are used for under water construction work, as well as for support for under water operations; and rescue recovery vessels are used to offer security services, such as oil spill preparedness, fire protection, rescue operation, and recovery at oil installations. In addition, the company offers renewable energy services comprising of cable repair, trenching and ploughing, mooring and towing, and daughter craft operations, and transport of equipment and good services. The company was founded in 2003 and is headquartered in Fosnavåg, Norway. Havila Shipping ASA is a subsidiary of Havila Holding AS.

Oslo Børs Benchmark Index_GI ended the session with HAVILA SHIPPING jumping 11.41% to €3.57 on Thursday while Oslo Børs Benchmark Index_GI rose 0.97% to €1,394.80.

Earnings Per Share

As for profitability, HAVILA SHIPPING has a trailing twelve months EPS of kr0.17.

PE Ratio

HAVILA SHIPPING has a trailing twelve months price to earnings ratio of 20.97. Meaning, the purchaser of the share is investing kr20.97 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.13%.

Moving Average

HAVILA SHIPPING’s value is way below its 50-day moving average of kr5.68 and way below its 200-day moving average of kr5.55.

Revenue Growth

Year-on-year quarterly revenue growth declined by 24.7%, now sitting on 405.18M for the twelve trailing months.

More news about HAVILA SHIPPING.

4. VIVORYON (VVY.AS)

9.53% Price Change

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

AEX-Index ended the session with VIVORYON rising 9.53% to €2.08 on Thursday, after two consecutive sessions in a row of losses. AEX-Index jumped 0.99% to €893.25, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.38%.

Volatility

VIVORYON’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.91%, a negative 0.48%, and a positive 4.63%.

VIVORYON’s highest amplitude of average volatility was 3.69% (last week), 2.88% (last month), and 4.63% (last quarter).

Volume

Today’s last reported volume for VIVORYON is 740451 which is 98.66% above its average volume of 372707.

Yearly Top and Bottom Value

VIVORYON’s stock is valued at €2.08 at 22:40 EST, way under its 52-week high of €14.10 and way above its 52-week low of €0.41.

More news about VIVORYON.

5. MOTORK (MTRK.AS)

8.21% Price Change

MotorK plc, together with its subsidiaries, provides software-as-a-service for the automotive retail industry in Italy, Spain, France, Germany, and the Benelux Union. The company offers a combination of automotive SaaS products and digital solutions to the digital lead generation, management, and nurturing process; and technology and software solutions for car manufacturers, dealers, and service centers. The company also provides WebSparK, a web platform for traffic acquisition and lead generation performance; LeadSparK, a CRM platform to support the activities of car dealerships and automotive manufacturers; and StockSparK, an automotive stock management platform. MotorK plc was incorporated in 2010 and is based in Milan, Italy.

AEX-Index ended the session with MOTORK rising 8.21% to €5.80 on Thursday while AEX-Index rose 0.99% to €893.25.

Earnings Per Share

As for profitability, MOTORK has a trailing twelve months EPS of €-0.28.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.52%.

Moving Average

MOTORK’s worth is under its 50-day moving average of €5.89 and way above its 200-day moving average of €4.68.

Revenue Growth

Year-on-year quarterly revenue growth declined by 2%, now sitting on 42.5M for the twelve trailing months.

Volume

Today’s last reported volume for MOTORK is 1233 which is 85.6% below its average volume of 8566.

Yearly Top and Bottom Value

MOTORK’s stock is valued at €5.80 at 22:40 EST, under its 52-week high of €6.10 and way higher than its 52-week low of €1.80.

More news about MOTORK.

6. VOW (VOW.OL)

7.62% Price Change

Vow ASA, together with its subsidiaries, produces, delivers, and maintains systems for processing and purifying wastewater, food waste, solid waste, and bio sludge in Norway, France, Poland, the United States, and Italy. The company operates through Industrial Solutions, Maritime Solutions, and Aftersales segments. The Industrial Solutions segment offers and designs plants for processing biomass, food products, and industry residues. The Maritime Solution segment delivers ship systems to shipyards for newbuild constructions, which include advanced wastewater purification, waste management, and food waste processing; and advanced systems to shipowners for ships. The Aftersales segment provides spare parts and consumables chemicals; and tailor-made service and maintenance programs. In addition, it offers Biogreen, a patented pyrolysis process for converting biomass, plastics, and waste into energy; Safesteril, a patented sterilisation process for food and pharmaceutical ingredients; and industrial robotics solutions, including robotic systems for waste recycling processes. Further, the company develops, designs, and fabricates industrial furnaces and equipment for heat treatment processes. It serves cruise, aquaculture, and landbased industries, as well as utilities. The company has a strategic partnership agreement with Repsol, S.A. for addressing the pressing issue of plastic waste; SAS IMPROVE for research and development of technological solutions; and Circon Energy, for equipment supply carbon refinery projects. The company was formerly known as Scanship Holding ASA and changed its name to VOW ASA in January 2020. Vow ASA was founded in 2011 and is headquartered in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with VOW rising 7.62% to €2.76 on Thursday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, VOW has a trailing twelve months EPS of kr-1.7.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.4%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 954.8M for the twelve trailing months.

More news about VOW.

7. IBA (IBAB.BR)

6.96% Price Change

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

BEL 20 ended the session with IBA rising 6.96% to €12.62 on Thursday while BEL 20 rose 0.5% to €4,216.75.

Earnings Per Share

As for profitability, IBA has a trailing twelve months EPS of €0.27.

PE Ratio

IBA has a trailing twelve months price to earnings ratio of 46.74. Meaning, the purchaser of the share is investing €46.74 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.86%.

Volatility

IBA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.49%, a negative 0.08%, and a positive 2.15%.

IBA’s highest amplitude of average volatility was 3.79% (last week), 2.48% (last month), and 2.15% (last quarter).

Volume

Today’s last reported volume for IBA is 52000 which is 129.03% above its average volume of 22704.

Moving Average

IBA’s value is higher than its 50-day moving average of €12.14 and above its 200-day moving average of €12.03.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jun 27, 2024, the estimated forward annual dividend rate is 0.17 and the estimated forward annual dividend yield is 1.57%.

More news about IBA.

8. SALMONES CAMANCHAC (SACAM.OL)

6.8% Price Change

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. (SNSE:SALMOCAM) operates as a subsidiary of Camanchaca S.A. (SNSE:CAMANCHACA).

Oslo Børs Benchmark Index_GI ended the session with SALMONES CAMANCHAC rising 6.8% to €22.00 on Thursday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-0.88.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.32%.

Moving Average

SALMONES CAMANCHAC’s worth is below its 50-day moving average of kr22.89 and way under its 200-day moving average of kr26.87.

Volume

Today’s last reported volume for SALMONES CAMANCHAC is 1154 which is 85.28% below its average volume of 7840.

More news about SALMONES CAMANCHAC.

9. ENDÚR (ENDUR.OL)

6.7% Price Change

Endúr ASA, together with its subsidiaries, operates as a supplier of construction and maintenance projects, services, and solutions for marine infrastructure businesses in Norway and the Norwegian Continental Shelf, Sweden, and internationally. The company operates through Marine Infrastructure, Aquaculture Solutions, and Other segments. It constructs and maintains facilities for land-based aquaculture, quays, harbors, dams, bridges, and other specialized concrete and steel projects. The company also offers maritime and ship maintenance and repair services. In addition, it produces concrete barges for the aquaculture industry. Endúr ASA was founded in 2007 and is based in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with ENDÚR rising 6.7% to €62.10 on Thursday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, ENDÚR has a trailing twelve months EPS of kr0.36.

PE Ratio

ENDÚR has a trailing twelve months price to earnings ratio of 172.5. Meaning, the purchaser of the share is investing kr172.5 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.43%.

More news about ENDÚR.

10. BENEVOLENTAI (BAI.AS)

6.22% Price Change

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI rising 6.22% to €0.84 on Thursday while AEX-Index rose 0.99% to €893.25.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.64.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.01%.

More news about BENEVOLENTAI.

Losers Today

1. ULTIMOVACS (ULTI.OL)

-21.97% Price Change

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ULTIMOVACS falling 21.97% to €1.90 on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.69%.

Yearly Top and Bottom Value

ULTIMOVACS’s stock is valued at kr1.90 at 22:40 EST, way below its 52-week low of kr2.25.

Moving Average

ULTIMOVACS’s value is way under its 50-day moving average of kr5.59 and way below its 200-day moving average of kr51.73.

More news about ULTIMOVACS.

2. NYRSTAR (NYR.BR)

-17.75% Price Change

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining of zinc and lead in Australia. The company was incorporated in 2007 and is based in Balen, Belgium.

BEL 20 ended the session with NYRSTAR dropping 17.75% to €0.04 on Thursday while BEL 20 jumped 0.5% to €4,216.75.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-0.01.

Volume

Today’s last reported volume for NYRSTAR is 145374 which is 405.45% above its average volume of 28761.

More news about NYRSTAR.

3. AELIS FARMA (AELIS.PA)

-16.95% Price Change

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.

CAC 40 ended the session with AELIS FARMA falling 16.95% to €4.36 on Thursday, after four consecutive sessions in a row of losses. CAC 40 jumped 0.52% to €7,435.07, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, AELIS FARMA has a trailing twelve months EPS of €-0.39.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.17%.

Volatility

AELIS FARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.20%, a negative 0.48%, and a positive 1.59%.

AELIS FARMA’s highest amplitude of average volatility was 3.20% (last week), 2.29% (last month), and 1.59% (last quarter).

Moving Average

AELIS FARMA’s worth is way below its 50-day moving average of €13.35 and way below its 200-day moving average of €13.72.

Yearly Top and Bottom Value

AELIS FARMA’s stock is valued at €4.36 at 22:40 EST, way under its 52-week low of €12.90.

Volume

Today’s last reported volume for AELIS FARMA is 1182 which is 109.94% above its average volume of 563.

More news about AELIS FARMA.

4. OXURION (OXUR.BR)

-10.71% Price Change

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

BEL 20 ended the session with OXURION sliding 10.71% to €0.70 on Thursday while BEL 20 rose 0.5% to €4,216.75.

Earnings Per Share

As for profitability, OXURION has a trailing twelve months EPS of €-100.

Moving Average

OXURION’s value is way below its 50-day moving average of €1.08 and way below its 200-day moving average of €2.56.

More news about OXURION.

5. HYLORIS (HYL.BR)

-9.57% Price Change

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium.

BEL 20 ended the session with HYLORIS dropping 9.57% to €5.18 on Thursday while BEL 20 rose 0.5% to €4,216.75.

Earnings Per Share

As for profitability, HYLORIS has a trailing twelve months EPS of €-0.55.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.08%.

Volatility

HYLORIS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.70%, a positive 0.15%, and a positive 7.27%.

HYLORIS’s highest amplitude of average volatility was 1.39% (last week), 5.13% (last month), and 7.27% (last quarter).

Volume

Today’s last reported volume for HYLORIS is 17434 which is 21.46% below its average volume of 22198.

Moving Average

HYLORIS’s worth is way under its 50-day moving average of €8.64 and way below its 200-day moving average of €11.25.

More news about HYLORIS.

6. LAVIDE HOLDING (LVIDE.AS)

-8.26% Price Change

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. is based in Amsterdam, the Netherlands.

AEX-Index ended the session with LAVIDE HOLDING dropping 8.26% to €0.22 on Thursday, after five successive sessions in a row of losses. AEX-Index rose 0.99% to €893.25, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.02.

Volume

Today’s last reported volume for LAVIDE HOLDING is 11542 which is 94.27% above its average volume of 5941.

More news about LAVIDE HOLDING.

7. NRC GROUP (NRC.OL)

-7.32% Price Change

NRC Group ASA, together with its subsidiaries, operates as a rail infrastructure company in Norway, Sweden, and Finland. It offers groundwork services, including excavations, transport, masses sorting, and ditching, as well as water and drainage systems; and signaling systems, digital telecom systems, electro, tracks, and station buildings and terminals, as well as catenary systems comprising wires, masts, switches, and return current systems. The company also provides complementary services, such as concrete work, recycling, demolition, and mass transport services; and specialized trackwork services. In addition, it offers railway construction and maintenance, civil construction, and environmental services; related infrastructure services, including bridges and crossings; and electrical installations for rail, light rail, and metro systems. The company was formerly known as Blom ASA and changed its name to NRC Group ASA in May 2015. NRC Group ASA was founded in 1966 and is headquartered in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with NRC GROUP dropping 7.32% to €3.23 on Thursday, after three consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.97% to €1,394.80, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, NRC GROUP has a trailing twelve months EPS of kr-11.46.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.7%.

Volume

Today’s last reported volume for NRC GROUP is 369677 which is 75.57% above its average volume of 210550.

Moving Average

NRC GROUP’s value is way under its 50-day moving average of kr9.82 and way below its 200-day moving average of kr11.13.

Sales Growth

NRC GROUP’s sales growth for the next quarter is 4%.

More news about NRC GROUP.

8. HYDRATEC (HYDRA.AS)

-6.71% Price Change

Hydratec Industries NV, through its subsidiaries, manufactures and sells industrial systems and plastic components for food, health, and mobility markets in the Netherlands, rest of Europe, Asia, North America, South America, Africa, and Oceania. It develops and produces sterilized product handling systems; and automated packaging solutions, including packaging for sterilized food in pouches, tins, and jars, as well as meal salads and agrifood in bags, nets, boxes, and crates. The company also supplies industrial incubators to produce day-old chicks; hatchery automation systems for processing of hatchery eggs and day-old chicks; climate control equipment for air and water treatment; hatchery management software for monitoring, analyzing, and optimizing of the incubation process; and service and support for hatchery systems operation. In addition, it manufactures extrusion equipment for PVC, PVC-O, and PO pipes; plastic injection molding products for use in climate control systems, lorries, bicycle parts, and coffee machines; rubber, metal, and plastic precision components, that includes dosing systems, functional and safety parts for braking systems, and cartridges for diagnostics and other medical applications. Hydratec Industries NV is headquartered in Amersfoort, the Netherlands. Hydratec Industries NV operates as a subsidiary of Hydra Investments B.v.

AEX-Index ended the session with HYDRATEC sliding 6.71% to €139.00 on Thursday, following the last session’s upward trend. AEX-Index rose 0.99% to €893.25, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, HYDRATEC has a trailing twelve months EPS of €15.41.

PE Ratio

HYDRATEC has a trailing twelve months price to earnings ratio of 9.02. Meaning, the purchaser of the share is investing €9.02 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.64%.

More news about HYDRATEC.

9. ASSYSTEM (ASY.PA)

-6.41% Price Change

Assystem S.A. provides engineering and infrastructure project management services worldwide. It provides engineering services for the preparation, design, and construction of critical and complex infrastructure projects for public authorities and utility companies. The company also offers engineering, procurement, and construction management; project management consulting; field operation management; siting, licensing, and environmental; systems engineering and design; industrial control system; and compliance, risk monitoring, safety, and security services, as well as digital transformation consulting, integrating business information system, data as a source of value, and digital twin services for nuclear, hydrogen, renewable, grids, transportation, cities and territorial development, and defense and security infrastructure sectors. In addition, it provides decommissioning and waste management services, and operation and maintenance services. The company was formerly known as AssystemBrime S.A. and changed its name to Assystem S.A. in June 2005. The company was founded in 1966 and is based in Courbevoie, France. Assystem S.A. is a subsidiary of HDL Development.

CAC 40 ended the session with ASSYSTEM dropping 6.41% to €46.05 on Thursday, after two sequential sessions in a row of losses. CAC 40 jumped 0.52% to €7,435.07, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, ASSYSTEM has a trailing twelve months EPS of €6.79.

PE Ratio

ASSYSTEM has a trailing twelve months price to earnings ratio of 6.78. Meaning, the purchaser of the share is investing €6.78 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.25%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ASSYSTEM’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

ASSYSTEM’s stock is valued at €46.05 at 22:40 EST, way below its 52-week high of €61.20 and way higher than its 52-week low of €37.20.

Volatility

ASSYSTEM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.05%, a negative 0.04%, and a positive 1.63%.

ASSYSTEM’s highest amplitude of average volatility was 0.87% (last week), 1.25% (last month), and 1.63% (last quarter).

Volume

Today’s last reported volume for ASSYSTEM is 41561 which is 238.72% above its average volume of 12270.

More news about ASSYSTEM.

10. REC SILICON (RECSI.OL)

-5.53% Price Change

REC Silicon ASA, together with its subsidiaries, produces and sells silicon materials for the solar and electronics industries worldwide. It offers various Signature Silane gas, a pure form of silicon that produces product for fuel industries comprising specialty gases, including Dichlorosilane, Monochlorosilane, and Disilane for use in the manufacturing processes of flat panel displays, semiconductors, and solar cells; solar grade polysilicon, including NextSi used for multi crystalline and monocrystalline solar ingot and wafer production in the manufacturing of solar modules; and electronic grade polysilicon consisting of float zone-based devices are used in motor control and power conversion processes for hybrid and electric vehicles, wind energy, and high voltage transmission, 5G communications, high-speed trains, internet of things, and big data, as well as Czochralski for manufacturing of semiconductor wafers used in memory processors, optics, and micro electromechanical systems. The company was formerly known as Renewable Energy Corporation ASA and changed its name to REC Silicon ASA in October 2013. REC Silicon ASA was founded in 1996 and is headquartered in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with REC SILICON sliding 5.53% to €6.32 on Thursday while Oslo Børs Benchmark Index_GI jumped 0.97% to €1,394.80.

Earnings Per Share

As for profitability, REC SILICON has a trailing twelve months EPS of kr-0.33.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -309.33%.

Volatility

REC SILICON’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.76%, a negative 0.55%, and a positive 2.84%.

REC SILICON’s highest amplitude of average volatility was 3.21% (last week), 2.58% (last month), and 2.84% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 155.1M for the twelve trailing months.

Moving Average

REC SILICON’s value is way below its 50-day moving average of kr7.47 and way below its 200-day moving average of kr10.17.

More news about REC SILICON.

Stay up to date with our winners and losers daily report